(Total Views: 562)
Posted On: 11/11/2025 4:42:14 PM
Post# of 158772
comments? - FDA removes black box warnings for estrogen therapy drugs for menopausal women.
-- these drugs were blackboxed and believed to have increased risks of cancers, risks of cardiovascular disease, stroke, breast cancer and dementia.
having trouble finding data - would like to know what happened between the time the blackbox was issued, why it was issued, the actual percentage of patients deemed affected directly from these drugs, and why today a change of heart. the articles ive read so far only mention that the benefits outweigh the risks, and nothing of the risks being downgraded.
leronlimab's ace in the hole is its safety record, and if the FDA is going to play loose with the facts and declare a dangerous drug as safe (aduhelm) then one of the main factors ive been sticking around for - the fact that leronlimab actually is factually safe - make not be as strong a point as i once assumed.
i truly believe that the current HIV drugs on the market have far more safety issues than leronlimab, and that leronlimab should be a preferred therapy over these marginally safe drugs. but what do i know.
am i wrong to assume that if leronlimab were to compete with the SOC drugs in the colorectal field, or in any of the 35+ indications weve all been aware of, that all things being equal (p value etc) that the drug with the better safety profile would be the winner? or am i just fantasizing?
-- these drugs were blackboxed and believed to have increased risks of cancers, risks of cardiovascular disease, stroke, breast cancer and dementia.
having trouble finding data - would like to know what happened between the time the blackbox was issued, why it was issued, the actual percentage of patients deemed affected directly from these drugs, and why today a change of heart. the articles ive read so far only mention that the benefits outweigh the risks, and nothing of the risks being downgraded.
leronlimab's ace in the hole is its safety record, and if the FDA is going to play loose with the facts and declare a dangerous drug as safe (aduhelm) then one of the main factors ive been sticking around for - the fact that leronlimab actually is factually safe - make not be as strong a point as i once assumed.
i truly believe that the current HIV drugs on the market have far more safety issues than leronlimab, and that leronlimab should be a preferred therapy over these marginally safe drugs. but what do i know.
am i wrong to assume that if leronlimab were to compete with the SOC drugs in the colorectal field, or in any of the 35+ indications weve all been aware of, that all things being equal (p value etc) that the drug with the better safety profile would be the winner? or am i just fantasizing?
(8)
(0)
